Atrial fibrillation - The growing epidemic

Heart

Volumn 93, Issue 5, 2007, Pages 542-543

  Lip, Gregory Y H ^a   Kakar, Puneet ^a   Watson, Timothy ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; WARFARIN;

CARDIOVASCULAR RISK; EDITORIAL; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART RHYTHM; HUMAN; INCIDENCE; ISCHEMIA; NATIONAL HEALTH SERVICE; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; STROKE; THROMBOEMBOLISM; UNITED KINGDOM; UNITED STATES; ADULT; AGED; EPIDEMIC; FEMALE; MALE; MIDDLE AGED; NOTE;

ADULT; AGED; ATRIAL FIBRILLATION; DISEASE OUTBREAKS; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 34247844426     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2006.110791     Document Type: Editorial

References (25)

1. Thrall G, Lane D, Carroll D, et al. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med 2006;119:448.
2. Freestone B, Lip GYH. Epidemiology and costs of cardiac arrhythmias. In: Lip GYH, Godtfredsen J, eds. Cardiac arrhythmias:a clinical approach. Edinburgh: Mosby, 2003;3-24).
3. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on projections for future prevalence. Circulation 2006;114:119-25.
4. Stewart S, Murphy N, Walker A, et al. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 2004;90:286-92.
5. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atria Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5.
6. Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994;271:840-4.
7. McGovern PG, Jacobs DR Jr, Shahar E, et al. Trends in acute coronary heart disease mortality, morbidity, and medical care from 1985 through 1997: the Minnesota heart survey. Circulation 2001;104:19-24.
8. Furberg CD, Psaty BM, Manolio TA, et al. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994;74:236-41.
9. Gersh BJ, Tsang TS, Barnes ME, et al. The changing epidemiology of non-valvular atrial fibrillation: the role of novel risk factors. Eur Heart J 2005;7:05-11.
10. Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004;110:1042-6.
11. Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006;27:949-53.
12. Murphy NF, Simpson CR, Jhund PS, et al. National survey of the prevalence, incidence, primary care burden and treatment of atrial fibrillation in Scotland. Heart, 2007, this issue..
13. Barakat K, Stevenson S, Wilkinson P, et al. Socioeconomic differentials in recurrent ischaemia and mortality after acute myocardial infarction. Heart 2001;85:390-4.
14. Wolf PA, Mitchell JB, Baker CS, et al. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med 1998;158:229-234.
15. Lip GYH, Boos C. Antithrombotic treatment in atrial fibrillation. Heart 2006;92:155-161.
16. Lip GYH, Edwards SJ. Stroke prevention with aspirin, warfarin and xilmelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Thromb Res 2006;118:321-33.
17. Lip GY, Karpha M. Anticoagulant and antiplatelet therapy use in patients with atrial fibrillation undergoing percutaneous coronary intervention: the need for consensus and a management guideline. Chest 2006;130:1823-7.
18. Stafford RS, Singer DE. National patterns of warfarin use in atrial fibrillation. Arch Intern Med 1996;156:2537-41.
19. Protheroe J, Fahey T, Montgomery AA, et al. The impact of patients' preferences on the treatment of atrial fibrillation: observational study of patient-based decision analysis. BMJ 2000;320:1380-4.
20. Solomon NA, Glick HA, Russo CJ, et al. Patient preferences for stroke outcomes. Stroke 1994;25:1721-5.
21. Lane DA, Ponsford J, Shelley A, et al. Patient knowledge and perceptions of atrial fibrillation and anticoagulant therapy: effects of an educational intervention programme. The West Birmingham Atrial Fibrillation Project. Int J Cardiol 2006;110:354-8.
22. National Collaborating Centre for Chronic Conditions. Atrial fibrillation: national clinical guideline for management in primary and secondary care. London: Royal College of Physicians, 2006.
23. Lip GYH, Tse HF. Management of atrial fibrillation. Lancet 2007; In press.
24. Cappato R, Calkins H, Chen SA, et al. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation 2005;111:1100-5.
25. Richter B, Derntl M, Marx M, et al. Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: no effect on ablation outcome after ablation of atrial fibrillation. Am Heart J 2007;153:113-19.